We performed RNA-seq on EGFR-mutant PC9 NSCLC cells treated with the EGFR inhibitor gefitinib and BRAF-mutant SKMEL28 melanoma cells treated with the BRAF inhibitor dabrafenib to investigate the scope of the transcriptional changes in each system and to uncover shared mechanisms of drug tolerance. Here, BRAF is linked to non-small cell lung carcinoma.